ALENTIS-THERAPEUTICS
Alentis Therapeutics, the Swiss biotech developing breakthrough treatments for fibrotic diseases, today announced that it has raised USD67 (CHF60) million in a Series B financing round. The funding will be used primarily for proof-of-concept clinical trials of Alentis’ first in class, Claudin-1 targeting, anti-fibrotic molecules in advanced liver and kidney fibrosis, and support ongoing drug discovery programs targeting other fibrotic diseases and hepatobiliary cancers.
Morningside Venture Investments led the financing, joined by Jeito Capital and Series A investors BioMed Partners, BB Pureos Bioventures, Bpifrance through its InnoBio 2 fund, High-Tech Gründerfonds and Schroders Capital.
"Our investors recognize the high unmet medical need,” said Dr. Roberto Iacone, CEO of Alentis, “They feel a great sense of urgency to develop innovative treatments for patients with life-threatening fibrotic diseases as well as related deadly cancers such as hepatocellular carcinoma and cholangiocarcinoma.” Dr. Iacone added, “This will fuel our strategy of expanding the indications for Claudin-1 targeting agents and further build our pipeline of proprietary product candidates.
Prof. Thomas Baumert, founder of Alentis, said that in the US and Europe alone, about 45% of deaths can be attributed to fibrotic disorders. He said that fibrosis affects nearly all tissues and organ systems such as the liver, kidneys and lungs.
“Fibrosis is an important risk factor for cancer, and Claudin-1 has a well-established role in cancer biology including tumor invasion and metastasis,” Prof. Baumert said. “Given the absent and unsatisfactory treatment options, it’s critical that we deliver new therapeutics for patients suffering from fibrosis and cancer.”
In addition, Alentis welcomed Jason Dinges of Morningside and Rafaèle Tordjman, founder and CEO of Jeito Capital, to its Board of Directors, effective immediately.
“We are excited about Alentis’ first-in-class approach to potentially enable effective treatments for fibrotic diseases with significant unmet medical need,” said Dr. Dinges. “We look forward to supporting this exceptional team as they pioneer modulation of Claudin-1, an important and highly promising target in fibrosis and oncology.”
“Our investment in Alentis is very much in line with Jeito’s goal to accelerate the growth of companies developing treatments for severely ill patients with no other options. We provide input into the science right through to the product’s market access,” said Dr. Tordjman. “Alentis has an outstanding and experienced team from pharma and biotech and is focused on a unique target, based on the founder’s work and his team of more than 10 years.”
Alentis' unique therapeutic approach focuses on the inhibition of Claudin-1 outside the tight junction and its downstream signalling acting on cell fate and plasticity. Alentis’ lead molecules ALE.F02 and ALE.C04 are highly selective anti-Claudin-1 mAb that recognize pathological overexpressed and conformation-dependent Claudin-1 epitopes in fibrotic disease and cancer. In preclinical studies, the lead molecule ALE.F02 modulates the function of non-junctional Claudin-1, preventing, and possibly reversing, the growth of fibrotic tissue within the liver and kidney by changing the plasticity of key cell types mediating fibrosis. Safety studies in non-human primates have supported translatability of the approach into patients. Alentis expects to initiate its first clinical trial in Q4 2021.
About Alentis Therapeutics
Alentis Therapeutics is a Swiss-based biotech that focuses on developing breakthrough treatments for fibrotic diseases. The company was founded in 2019 based on ground-breaking research in the laboratory of Prof. Thomas Baumert MD at the University of Strasbourg and the French National Institute of Health (Inserm).
The Company’s lead candidates are monoclonal antibodies that are highly selective for Claudin-1, a novel, previously unexploited target with a unique mechanism of action that plays a key role in the pathology of liver fibrosis and fibrosis-driven hepatobiliary cancers. It also has early discovery programs exploring the potential of Claudin-1 inhibition in the treatment of fibrosis of other tissues including the kidney and lung. These represent very large and expanding markets with high unmet need. Furthermore, the company uses a patient-derived drug and target discovery platform to develop medicines for advanced fibrosis.
Unlike current therapies in fibrosis, which mostly address the disease indirectly, Alentis’ pioneering approach has the potential to directly modify and reverse the course of disease progression.
Alentis is headquartered in Basel’s pharma-biotech hub in Switzerland with a subsidiary for R&D in Strasbourg, France.
For more information, visit https://alentis.ch/
View source version on businesswire.com: https://www.businesswire.com/news/home/20210614005688/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Andersen Consulting styrker sit udbud inden for digital transformation med Silver Creek23.1.2026 14:25:00 CET | Pressemeddelelse
Andersen Consulting annoncerer en samarbejdsaftale med Silver Creek, en førende virksomhed inden for datastrategi, analyse, applikationsudvikling og ai-drevne automatiseringstjenester. Silver Creek Software er en førende teknologivirksomhed, der er baseret i Alberta, Canada, med ekspertise i at transformere organisationer gennem data- og forretningsløsninger. Firmaet blev etableret i 1998 og tilbyder komplette konsulentydelser med speciale i data og analyse, applikationsudvikling, maskinlæring og ai. Med et team af erfarne og certificerede fagfolk leverer virksomheden skræddersyede løsninger på tværs af flere brancher, herunder den offentlige sektor, finansielle tjenester, naturressourcer og transport. Kernen i Silver Creeks arbejde er at skabe værdi ud fra kundens data gennem digitalisering, integration og automatisering. "Vi har opbygget vores omdømme på at hjælpe organisationer med at omdanne komplekse dataøkosystemer til strategiske aktiver," udtaler Ben Steem, administrerende dire
DCX Liquid Cooling Systems Announces New 8MW Coolant Distribution Unit, Optimized for 45°C Warm-Water Cooling in Next-Gen NVIDIA Vera Rubin AI Deployments23.1.2026 14:18:00 CET | Press release
DCX beats its own record of the most powerful CDU system ever made. Liquid cooling Manufacturer leads category of hyperscale CDUs, launching today a new CDU system with a stunning 8MW capacity, designed specifically for NVIDIA Vera Rubin 45°C warm water cooling DCX Liquid Cooling Systems is proud to announce the second generation Facility Distribution Unit (FDU V2AT2). Designed to support the infrastructure shift driven by AI deployments at scale, new CDU supports 45°C warm-water cooling for NVIDIA’s NVL72 GB200 / GB300 Blackwell and Vera Rubin architectures. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260123068139/en/ The Facility Coolant Distribution Unit—the new generation of liquid cooling for hyperscale data centers. FDU V2AT2 delivers up to 8.15MW of heat transfer capacity while providing record breaking flowrate, enabling 45°C warm-water operation—temperature level that can eliminate the need for chillers on the he
HUMAIN and Infra Announce AI and Digital Financing Framework Agreement23.1.2026 14:01:00 CET | Press release
HUMAIN and the National Infrastructure Fund (“Infra”) announced on the sidelines of the World Economic Forum (WEF) Annual Meeting 2026 in Davos, Switzerland, a Strategic Financing Framework Agreement of up to $1.2 billion to support the expansion of AI and digital infrastructure projects in the Kingdom of Saudi Arabia. The Framework Agreement outlines non-binding financing terms for HUMAIN’s development of up to 250 MW of hyperscale AI data center capacity. These data centers will deploy leading edge GPUs for AI training and inference and support HUMAIN’s local, regional and global customers. In addition, Infra and HUMAIN have agreed to explore the establishment of an AI data center investment platform. This would be anchored by the two organizations and structured to facilitate participation by global and local institutional investors to support further scaling of HUMAIN’s AI strategy. Today’s Framework Agreement underscores Infra’s key role in partnering with its counterparts to acce
Cyclic Materials Secures USD $75M Series C Funding to Fast-Track Local and Resilient Rare Earths Supply at Global Scale23.1.2026 13:00:00 CET | Press release
New equity investment will accelerate deployment of resilient, locally anchored rare earths recycling infrastructure enabling new streams of heavy rare earths supply for AI, robotics, defense and advanced manufacturing critical to the future of Western industry Cyclic Materials today announced it has closed an over-subscribed USD $75 million Series C equity round, its largest to date, scaling up operations across the US and Europe and accelerating Canada-based research and development footprint. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260123519008/en/ Cyclic Materials’ Mesa, Arizona site, the very first scale-up of a commercial plant for recycling and local production of rare earths in the US, with a focus on heavy and light rare earth magnets. The recycling of magnet-containing end-of-life (EOL) scrap and magnet production waste is the fastest way to the production of magnet rare earth elements (REEs) in Western coun
SLB Announces Fourth-Quarter and Full-Year 2025 Results, Increases Dividend and Commits to Return More Than $4 Billion to Shareholders in 202623.1.2026 12:50:00 CET | Press release
Fourth-quarter revenue of $9.75 billion increased 9% sequentially and 5% year on year Fourth-quarter GAAP EPS of $0.55 increased 10% sequentially and decreased 29% year on year Fourth-quarter EPS, excluding charges and credits, of $0.78 increased 13% sequentially and declined 15% year on year Fourth-quarter net income attributable to SLB of $824 million increased 12% sequentially and decreased 25% year on year Fourth-quarter adjusted EBITDA of $2.33 billion increased 13% sequentially and decreased 2% year on year Fourth-quarter cash flow from operations was $3.01 billion and free cash flow was $2.29 billion Board approved a 3.5% increase in quarterly cash dividend to $0.295 per share Full-year revenue of $35.71 billion decreased 2% year on year Full-year GAAP EPS of $2.35 decreased 24% year on year Full-year EPS, excluding charges and credits, of $2.93 decreased 14% year on year Full-year net income attributable to SLB of $3.37 billion decreased 24% year on year Full-year adjusted EBIT
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom